Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis

Kim, Jeong Eun; Lee, Dong Hoon; Choi, Yun Suk; Yoon, Dok Hyun; Kim, Sang We; Suh, Cheolwon; Lee, Jung Shin

doi:10.1016/j.lungcan.2008.12.011

Cited by 196 publications

(124 citation statements)

References 14 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Gefitinib, as a novel target therapeutic drug, has been commonly used for treating NSCLC in recent years. Some retrospective analyses showed that gefitinib were also effective in patients with BM from NSCLC and brought the median OS of 9-13.5 months to patients (Heimberger AB et al, 2002;Ceresoli et al, 2004;Hotta, 2004;Namba et al, 2004;Takahashi et al, 2004;Shimato et al, 2006;Kim et al, 2009). A phase II study by Ma et al (2009) reported that the median overall survival of patients with BM under the treatment of gefitinib with concomitant WBRT was 13 months.…”

Section: Discussionmentioning

confidence: 99%

“…Gefitinib, a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), was reported to be effective and brought the median OS of 9-13.5 months to patients with BM from NSCLC (Heimberger et al, 2002;Ceresoli et al, 2004;Hotta, 2004;Namba et al, 2004;Takahashi et al, 2004;Shimato et al, 2006;Kim et al, 2009). With the concept of the disruption of blood brain barrier (BBB) by BM and radiation therapy, gefitinib with small molecular weight may have the ability to penetrate the BBB (Fidler et al, 2002;Van et al, 2002;Jackman et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

Yin¹,

Zhang²,

Liao³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Gefitinib, a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), is used both as a single drug and concurrently with whole brain radiotherapy (WBRT) the standard treatment for brain metastases (BM), and is reported to be effective in a few small studies of patients with BM from non-small-cell lung cancer (NSCLC). However, no study has compared the two treatment modalities.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

Yin¹,

Zhang²,

Liao³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Even at these concentrations, however, disease response in the CNS was witnessed [46]. In a case series of 23 Korean patients with untreated brain metastases who were treated with erlotinib 150 mg daily or gefitinib 250 mg daily, intracranial disease response was achieved in 69.6 % and intracranial disease control was witnessed in 82.6 % of patients [47]. High dose erlotinib given at 600 mg every 4 days or 300 mg every other day has demonstrated efficacy in controlling CNS metastases with tolerable side effects in 2 case reports [46,48,49].…”

Section: Cns Penetrationmentioning

confidence: 99%

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer

Thompson

Menon

2016

ADMET DMPK

View full text Add to dashboard Cite

Discovery of the epidermal growth receptor (EGFR) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements has expanded the therapeutic landscape in non-small cell lung cancer (NSCLC). Survival outcomes for patients with these mutations have improved dramatically with EGFR and ALK tyrosine kinase inhibitors (TKIs). Multiple generations of EGFR and ALK TKIs have been rapidly developed, and patients and clinicians now have several options for first-and second-line treatments. While these small molecule

show abstract

“…Whole-brain radiotherapy (WBRT) for asymptomatic brain metastases can reduce performance status and delay systemic treatment, so primary chemotherapy can be a feasible alternative treatment [27]. Recent studies [28] showed that the blood-brain Barrier (blood brain barrier, BBB) has been destroyed in the process of brain metastases, and with whole brain radiotherapy, mannitol and other dehydration drugs can make the BBB open in a variety degrees, which allows chemotherapy drugs across the blood -brain barrier into the central nervous system to kill tumor cells.…”

Section: Chemotherapeuticsmentioning

confidence: 99%

The proceedings of brain metastases from lung cancer

Zhao

et al. 2016

Open Life Sciences

View full text Add to dashboard Cite

States, making this the most common complication of systemic cancer. Lung cancer's primary tumors are the most frequent source of brain metastases, accounting for approximately 48%-60% of all those diagnosed [1]. Brain metastases of patients with lung cancer include both non-small-cell (NSCLC) and small-cell (SCLC) histologists [2]. Brain metastases (BM) from non-small cell lung cancer (NSCLC) are about 20%, autopsy up to 40% [3]. Approximately 10% of SCLC patients have brain metastases (BM) at diagnosis and an additional 40% will develop central nervous system (CNS) involvement during their disease course [4], 2 years later, it can reach 80% [5]. The natural median survival of lung cancer with brain metastasis patients is only about one month [6]. The mechanism of lung cancer with brain metastasis is complicated. Thus, it is a great challenge to prevent and develop therapeutic options for brain metastasis from lung cancer. The mechanisms of lung cancer with brain metastasesMultiple mechanisms are involved in the development and progression of lung cancer with brain metastasis, the main influencing factors of lung cancer with brain metastases are as follows: Nerve -immune adjustment factorVagal nerves play an important role in the interaction of nervous and immune systems. It can be observed that the incidence and metastases of lung tumors increased after the role of vagal nerves in clinical and animal experiments. An airway sensor is a kind of biological sensor which can identify a variety of mediators and cytokines in the process of lung inflammation, the related signal can be transferred to the brain via vagus and induce the brain metastases, which then generates a series of reactions to regulate the Abstract: Brain tumors include primary tumors of various intracranial tissue and secondary intracranial tumors that transferred from other parts of the body. Secondary intracranial tumors are especially prevalent in patients with lung cancer. The mechanisms of lung cancer with brain metastases are complicated, they are affected by a variety of factors. Thus, identifying the mechanisms of lung cancer with brain metastases will have far-reaching meanings both for clinic pharmacy research and for a better quality of life for patients; Brain metastases from lung cancer represent a prevalent and challenging clinical dilemma, and some research suggests that the outcomes and characteristics of brain metastases that result from lung cancer primary sites are perhaps different than those from other primary sites, therefore increasing the difficulty of clinical treatment. Despite steady research developments during recent years, the survival rates remain poor. The mechanisms and therapeutic options for treating brain metastases arising from lung cancer are review in this article.

show abstract

Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis

Cited by 196 publications

References 14 publications

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer

The proceedings of brain metastases from lung cancer

Contact Info

Product

Resources

About